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Abstract
Background: Echocardiographic characteristics across the spectrum of chronic kidney disease (CKD) have not been
well described. We assessed the echocardiographic characteristics of patients with preserved renal function and
mild or moderate CKD referred for echocardiography and determined whether echocardiographic parameters of
left ventricular (LV) and right ventricular (RV) structure and function were associated with changes in renal function
and mortality.
Methods: This retrospective cohort study enrolled all adult patients who had at least one trans-thoracic echocardiography
between 2004 and 2014 in our institution. The composite outcome of doubling of serum creatinine or
initiation of maintenance dialysis or kidney transplantation was the primary outcome. Mortality was the
secondary outcome.
Results: 29,219 patients were included. Patients with worse renal function had higher prevalence of structural
and functional LV and RV abnormalities. Higher estimated glomerular filtration rate (eGFR) was independently
associated with preserved LV ejection fraction, preserved RV systolic function, and lower LV mass, left atrial
diameter, pulmonary artery pressure, and right atrial pressure, as well as normal RV structure. 1041 composite
renal events were observed. 8780 patients died during the follow-up. Pulmonary artery pressure and the RV,
but not the LV, echocardiographic parameters were independently associated with the composite renal outcome. In
contrast, RV systolic function, RV dilation or hypertrophy, LV ejection fraction group, LV diameter quartile, and pulmonary
artery pressure quartile were independently associated with all-cause mortality.
Conclusions: Echocardiographic abnormalities are frequent even in early CKD. Echocardiographic assessment particularly
of the RV may provide useful information for the care of patients with CKD.
Keywords: Echocardiography, Chronic kidney disease, Doubling of serum creatinine, Dialysis, Kidney transplantation,
Mortality
Background
Chronic kidney disease (CKD) is highly prevalent among
patients with congestive heart failure (CHF) and is asso-
ciated with higher mortality rates [1]. In the CHARM
trials, for example, an estimated glomerular filtration
rate (eGFR) < 60 ml/min/1.73m2 was an independent
predictor of cardiovascular death or admission for de-
compensated heart failure [2].
Echocardiography can identify abnormalities in heart
function or structure that are associated with kidney dys-
function [3]. Abnormal left ventricular (LV) geometry,
lower mid-wall fractional shortening, and higher LV mass
index have been described among patients with CKD
compared with patients with preserved renal function in a
cohort of participants with heart failure with preserved
ejection fraction [3]. In other studies, echocardiographic
parameters predicted cardiovascular events among CKD
patients, although there was no net reclassification
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improvement when these parameters were added to a
model including clinical and laboratory variables [4].
Although these data are intriguing, the echocardiographic
characteristics of patients across the spectrum of cardiac
function – with both preserved or reduced LV ejection frac-
tion and with or without CHF – have not been adequately
described across different eGFR stages, especially in pa-
tients with mildly decreased eGFR. It is also uncertain
whether echocardiographic parameters predict CKD pro-
gression. The objective of this study was to describe the
echocardiographic characteristics of patients with preserved
renal function and mild or moderate CKD referred for
echocardiography, and to assess associations of echocardio-
graphic parameters with changes in renal function.
Methods
Study population
Patients were included if they had at least one
trans-thoracic echocardiography with tissue Doppler im-
aging at a Partners affiliated healthcare facility between
January 1st 2004 and January 6th 2014, were ≥ 18 years
old at the time of echocardiography, and had at least
one eGFR between 30 and 120 ml/min/1.73m2 during
this time period. For patients who had more than one
echocardiogram, the first one was used.
Patients on maintenance dialysis or a history of kidney
or heart transplant were excluded, as were those without
creatinine values from 365 days before to 90 days after
echocardiography.
The study was designed to capture patients with pre-
served renal function and mild or moderate CKD
(eGFR≥90, 60–89, 30–59 ml/min/1.73m2).
Data collection
The Research Patient Data registry (RPDR), a registry of
all patients followed at a Partners healthcare facility, was
used to retrieve all encounters, medication prescriptions,
laboratory tests, and echocardiography results conducted
during this time period.
To avoid misdiagnosis of acute kidney injury at the
time of baseline echocardiography as CKD, the average
baseline creatinine was calculated using all the available
creatinines for each patient from 365 days prior to
90 days after the index echocardiogram (16 values on
average, median of 7). Baseline eGFR was calculated
using the CKD-EPI equation.
Comorbidities and baseline data
Information on comorbidities was extracted using
condition-specific diagnostic codes (International Classi-
fication of Diseases, 9th revision-Additional file 1 Table
S1). Comorbidities were diagnosed on the basis of rele-
vant inpatient or outpatient diagnoses preceding the
echocardiography date. As many echocardiograms are
performed during a first admission for decompensated
heart failure, any patient with a first CHF diagnostic
code in the 30 days after the echocardiogram was con-
sidered to have baseline CHF.
The following baseline laboratory data were extracted
(the values closest to the echocardiogram date, from
365 days before to 90 days after echocardiography):
hemoglobin, albumin, calcium, phosphorus, urine albu-
min to creatinine ratios, and brain natriuretic peptide
(BNP) levels.
We determined the use of angiotensin converting en-
zyme inhibitors (ACEI), angiotensin receptor blockers
(ARB), β-blockers, statins, aspirin, clopidogrel, and war-
farin by matching the most recent outpatient medication
lists with generic and brand name drugs.
Echocardiograms
The following parameters were extracted from the echo-
cardiography reports using automated text processing:
LV ejection fraction, LV diastolic diameter, LV posterior
wall thickness, interventricular septal thickness in dia-
stole, LV mass (area-length method), LV mass index
(corrected for body surface area), pulmonary artery pres-
sure, right atrial pressure, left atrium diameter, aortic
root diameter, concentric hypertrophy and regional wall
motion abnormalities, right ventricular (RV) systolic
function (preserved or reduced), and RV hypertrophy or
dilatation (presence or absence). All echocardiogram re-
ports were acquired and recorded using an American
Society of Echocardiography-recommended scanning
protocol with standard techniques. Although we initially
planned to examine associations of diastolic dysfunction
with CKD progression, tissue Doppler imaging results
were image-embedded and not readily extractable.
We randomly reviewed 100 patient records to check
the accuracy of automated extraction of diagnoses,
medication, and echocardiographic parameters. Specifi-
city was 100% and sensitivity was between 95 and 97%
for the different echocardiographic parameters (most
available information was captured using regular expres-
sion searches).
Outcomes
We retrospectively searched in the registry for available cre-
atinine values or diagnostic codes post index echocardiog-
raphy. The composite of doubling of serum creatinine,
maintenance dialysis or kidney transplantation was the pri-
mary outcome because it is a standard, FDA-validated out-
come. Mortality was the secondary outcome. We also
analyzed associations between echocardiographic parame-
ters and eGFR, using the latter as the exposure.
Clinical outcomes were identified from RPDR using
diagnostic codes. The RPDR is continuously matched to
the social security death index, a national database
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including all deaths in the United States. For the out-
come of doubling of serum creatinine, creatinine values
starting 30 days after the first doubling as well as the last
available creatinine were screened for repeated/con-
firmed doubling to rule out potential AKI. Patients were
censored at the last clinical visit or lab test.
Statistical analysis
Baseline characteristics across eGFR groups were com-
pared using the χ2 test for categorical variables, and
one-way analysis of variance or non-parametric trend
tests for continuous variables.
In order to study the association between echocardio-
graphic parameters and eGFR, we used linear regression
for continuous echocardiographic variables or logistic re-
gression for binary variables. Normality, linearity, and ho-
moscedasticity assumptions were confirmed using
graphical methods. The following covariates were included
in multivariate models on the basis of known associations
with the outcomes of interest, clinical intuition, and avail-
ability in the dataset: age, sex, race, history of hypertension,
diabetes, coronary disease, CHF, and use of ACEI or ARB.
In order to assess event-free survival, the cohort was
divided into quartiles for LV diastolic diameter, LV mass,
LV mass index, left atrium diameter, and pulmonary ar-
tery pressure. Categorical variables or variables reported
in intervals rather than as true continuous measure-
ments were assessed in binary categories (RV systolic
function, RV hypertrophy and dilation, and right atrial
pressure) except for LV ejection fraction where the fol-
lowing cutoffs were used: < 25%, 25–39%, 40–54%,
≥55%. The incidence of the composite renal outcome
was calculated for each quartile. The χ2 test was used to
compare the different groups. To assess associations of
echocardiographic parameters with clinical outcomes,
multivariable Cox proportional hazards regression was
used. Proportional hazards assumptions were verified
using graphical methods. Patients without available
creatinine values or diagnostic codes for dialysis or
transplantation were considered to have stable renal
function. The following parameters were included in the
baseline model: age, sex, race, baseline eGFR, history of
hypertension, diabetes, coronary artery disease, CHF,
and use of ACEI or ARB. The various echocardiographic
parameters were then added to the model. Patients with
missing echocardiographic parameters were excluded
from the respective survival analysis.
We conducted three sensitivity analyses in the follow-
ing subgroups: i) outpatients only—in order to exclude
individuals with echocardiograms during an acute car-
diac event; ii) individuals without CHF at baseline; iii)
individuals with available follow-up creatinine values or
diagnostic codes.
P-values < 0.05 were considered statistically significant.
SPSS software (version 20.0, SPSS Inc., Chicago, IL,
USA) was used for all statistical analyses.
Results
Echocardiographic parameters in different eGFR groups
We identified 42,446 patients with at least one echocardio-
gram and one eGFR value between 30 and 120 ml/min/
1.73m2. Of these, 31,173 had at least one creatinine value
available from 365 days before to 90 days after the echocar-
diogram. 492 patients with a transplanted heart or kidney,
268 patients on dialysis at baseline, and 1194 patients who
had a baseline eGFR < 30 ml/min/1.73 m2 were excluded
from the main analysis. The characteristics of the 29,219
patients with an eGFR ≥30 ml/min/1.73m2 at baseline are
depicted in Table 1. Mean time between echocardiography
and serum creatinine was 2.3 ± 0.1 days. Patients with
worse renal function were older, more commonly white,
had a higher prevalence of hypertension, diabetes, coronary
artery disease, or heart failure, higher urine albumin to cre-
atinine ratios, and higher potassium and phosphorus levels.
BNP levels were also higher with increasing creatinine.
Patients with worse renal function had lower LV ejec-
tion fraction, higher prevalence of RV systolic impair-
ment, higher LV mass index, higher LV and left atrium
diameter, more regional wall motion abnormalities, and
higher prevalence of RV hypertrophy or dilated RV
(Table 2). They also had higher pulmonary artery
pressures, and higher prevalence of elevated right atrial
pressure. eGFR was independently associated with all
echocardiographic parameters analyzed in multi-variable
models (Additional file 2 Table S2).
Echocardiographic parameters in patients with and
without history of CHF
A total of 8183 patients had history of CHF: 1733 (21%)
with an eGFR ≥90, 3369 (41%) with an eGFR of 60–89,
and 3081 (38%) with an eGFR < 60 ml/min/1.73m2. The
baseline and echocardiographic characteristics according
to eGFR groups of patients with CHF are shown in
Additional file 3: Table S3 and Additional file 4: Table S4.
In the subgroup of patients without CHF, prevalence
of various comorbidities at baseline was lower compared
with patients with CHF. In those without CHF, right
atrial pressure levels were similar in all three eGFR
groups. For all the other echocardiographic parameters,
a significant linear trend was identified across the differ-
ent eGFR groups but the prevalence of RV or LV systolic
dysfunction was lower (Additional file 5: Table S5 and
Additional file 6: Table S6).
Renal outcomes
At least one follow-up creatinine (beyond day 90 from
the index echocardiogram) or diagnostic code for
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dialysis/transplantation were available for 20,008 patients
(68%). Median follow up was 48 months (interquartile
range 20–87 months). A total of 1041 composite renal
events were observed: 691 events with the creatinine
doubling, 273 initiations of dialysis, and 77 kidney
transplantations; 282 occurred in patients with an
eGFR ≥90 (0.86 events per 100 patients-years), 348 in
patients with eGFR between 60 and 89 (0.73 events
per 100 patients-years), and 411 in patients with an eGFR
< 60 ml/min/1.73m2 (1.79 events per 100 patients-years).
The number of composite renal events that occurred
in the 1st, 2nd, 3rd, and 4th quartile of each echocardio-
graphic parameter is depicted in Fig. 1. An increase was
observed in higher quartiles of LV and left atrial diam-
eter, LV mass and pulmonary artery pressure but not of
LV mass index. Lower LV ejection fraction groups also
had higher renal event rates. However, in adjusted
models, most LV parameters were not independently
associated with the composite renal outcome, with the
exception of the second quartile of LV diastolic diameter
Table 1 Baseline characteristics of the study patients
Characteristic eGFR 90–120 eGFR 60–89 eGFR 30–59
N Result N Result N Result
Patients 9864 (34%) 12,731 (43%) 6624 (23%)
Outpatients 4558 (46%) 6124 (48%) 2448 (37%)
Age (years) 9864 50 ± 14 12,731 64 ± 13 6624 72 ± 12
Male sex 9864 4797 (49%) 12,731 6608 (52%) 6624 3281 (50%)
African American 9864 1168 (12%) 12,731 949 (8%) 6624 523 (8%)
Hypertension 9864 3480 (35%) 12,731 6884 (54%) 6624 4091 (62%)
Diabetes mellitus 9864 1308 (13%) 12,731 2307 (18%) 6624 1902 (29%)
CAD 9864 3087 (31%) 12,731 5984 (47%) 6624 3762 (57%)
CHF 9864 1733 (18%) 12,731 3369 (27%) 6624 3081 (47%)
COPD 9864 286 (3%) 12,731 454 (4%) 6624 319 (5%)
PE 9864 520 (5%) 12,731 452 (4%) 6624 257 (4%)
ACEI 8953 1614 (18%) 11,642 3278 (28%) 6175 2222 (36%)
ARB 8953 330 (4%) 11,642 928 (8%) 6175 810 (13%)
β-blocker 8953 3618 (40%) 11,642 6190 (53%) 6175 3902 (63%)
Statin 8953 2298 (26%) 11,642 5077 (44%) 6175 3317 (54%)
Aspirin 8953 2993 (33%) 11,642 5287 (45%) 6175 3373 (55%)
Clopidogrel 8953 659 (7%) 11,642 1325 (11%) 6175 844 (14%)
Warfarin 8953 940 (11%) 11,642 1852 (16%) 6175 1168 (19%)
Creatinine (μmol/l) 9864 65 (57–74) 12,731 82 (73–94) 6624 115 (100–134)
eGFR (ml/min/1.73m2) 9864 104 ± 12 12,731 76 ± 9 6624 47 ± 8
Albuminuria stage:
- A1 348 213 (61%) 544 333 (61%) 472 188 (40%)
- A2 348 100 (29%) 544 159 (29%) 472 191 (41%)
- A3 348 35 (10%) 544 52 (10%) 472 93 (20%)
Hb (g/l) 7115 123 ± 23 8458 127 ± 21 4301 118 ± 21
Albumin (g/l) 7331 38 ± 7 9261 39 ± 6 5183 37 ± 6
K+ (mmol/l) 9522 4.0 ± 0.4 12,312 4.0 ± 0.4 6448 4.1 ± 0.5
Calcium (mmol/l) 8491 2.20 ± 0.18 10,961 2.23 ± 0.15 5796 2.23 ± 0.18
Phos (mmol/l) 3974 1.0 (0.8–1.2) 4188 1.0 (0.9–1.2) 2917 1.1 (0.9–1.2)
BNP (ng/L) 906 90 (27–265) 1610 188 (62–480) 1519 349 (137–745)
Results are presented as number (percentage), mean ± standard deviation, or median (interquartile range). eGFR, estimated glomerular filtration rate; N, number of
patients with available data; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive lung disease; PE, pulmonary embolism (acute or
chronic); ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; A1: albuminuria < 30 mg/g of creatinine; A2: albuminuria 30–300 mg/g of
creatinine; A3: albuminuria > 300 mg/g of creatinine; Hb, hemoglobin; K+, potassium; Phos, phosphorus; BNP, brain natriuretic peptide. Percentages are within eGFR
group and exclude missing values. The three eGFR groups were statistically different (P value for trend < 0.001 for all parameters except sex)
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Table 2 Echocardiographic characteristics of the study patients
eGFR 90–120 eGFR 60–89 eGFR 30–59
Characteristic N Result N Result N Result
Preserved EF 9161 7604 (83%) 11,730 8975 (77%) 6192 4058 (66%)
LVEF (%) 9161 60 (55–60) 11,730 60 (55–60) 6192 55 (45–60)
LVd (cm) 7576 4.66 ± 0.72 9562 4.64 ± 0.80 5411 4.70 ± 0.93
LVPW (cm) 5247 0.98 ± 0.22 6141 1.04 ± 0.23 3431 1.09 ± 0.25
IVSd (cm) 6918 1.02 ± 0.24 8759 1.10 ± 0.25 4975 1.15 ± 0.26
LVM (g) 3853 161 (126–205) 4229 174 (135–223) 2377 186 (146–243)
LVMi (g/m2) 2857 85 (69–103) 3204 92 (74–115) 1705 102 (81–128)
LAd (cm) 7299 3.66 ± 0.72 9277 3.92 ± 0.78 5245 4.14 ± 0.83
PAP (mmHg) 5309 22 (18–28) 7385 25 (19–31) 4359 28 (22–37)
RAP > 6 cm H2O 3831 283 (7%) 4400 449 (10%) 2317 372 (16%)
Impaired RV systolic function 7810 430 (6%) 9887 789 (8%) 5376 717 (13%)
Increased RV diameter 7982 728 (9%) 10,148 1114 (11%) 5555 907 (16%)
RV hypertrophy 4990 117 (2%) 5888 171 (3%) 2840 172 (6%)
ARd (cm) 6946 3.09 ± 0.47 8927 3.18 ± 0.47 5052 3.18 ± 0.48
RWMA 6320 348 (6%) 7366 718 (10%) 3377 540 (16%)
Results are presented as number (percentage), mean ± standard deviation, or median (interquartile range). N, number of patients with available data; LVEF, left
ventricular ejection fraction; EF, ejection fraction; LVd, left ventricular diastolic diameter; LVPW, left ventricular posterior wall thickness; IVSd, interventricular septal
thickness in diastole; LVM, left ventricular mass (area-length method); LVMi, left ventricular mass index (corrected for body surface area); LAd, left atrium diameter;
PAP, pulmonary artery pressure; RAP, right atrial pressure; RV, right ventricle; ARd, aortic root diameter; RWMA, regional wall motion abnormalities. Percentages
exclude missing values. The three eGFR groups were statistically different (P value for trend < 0.001 for all parameters except LVd; p = 0.01 for LVd)
Fig. 1 Percentage of patients with CKD progression by category of echocardiographic parameters. The incidence of the composite renal outcome
(doubling of serum creatinine or initiation of maintenance dialysis or kidney transplantation) was calculated for each quartile of LVd, LVM, LVMi, LAd,
and PAP. For LVEF, the following cutoffs were used: < 25%, 25–39%, 40–54%, ≥55%. P values are for trend. LVEF, left ventricular ejection fraction; LVd,
left ventricular diastolic diameter; RV, right ventricular; LVMi, left ventricular mass index (corrected for body surface area); LA d, left atrium diameter;
PAP, pulmonary artery pressure. P for trend provided
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(Table 3). In contrast, pulmonary artery pressure and RV sys-
tolic function and dilation were independent predictors of
the composite renal outcome. The adjusted HR for impaired
RV systolic function was 1.51 (95% CI 1.21–1.88, p < 0.001),
and for RV dilation 1.59 (95% CI 1.32–1.92, p < 0.001).
Mortality
8780 patients died during the follow-up: 2118 (24% of
deaths) among patients with an eGFR ≥90 (6.4 events
per 100 patients-years), 3456 (39% of deaths) among pa-
tients with eGFR between 60 and 89 (7.2 events per 100
patients-years), and 3206 (37% of deaths) among pa-
tients with eGFR < 60 ml/min/1.73 m2 (13.6 events per
100 patients-years).
In adjusted models, LV ejection fraction group, LV
diameter quartile, pulmonary artery pressure quartile,
and RV parameters were independently associated with
mortality (Table 3).
Sensitivity analyses
Adjusted results were qualitatively similar in analyses of
the 13,130 outpatients (Additional file 7: Table S7).
Results were also similar in those without baseline CHF
(n = 21,036, Additional file 8: Table S8), except that RV
hypertrophy was not significantly associated with mor-
tality, and in patients with available follow-up renal tests
or codes (n = 20,008, Additional file 9: Table S9).
Discussion
We assessed echocardiographic characteristics of pa-
tients with preserved renal function and mild or moder-
ate CKD in a cohort of individuals referred for
echocardiography. We found that patients with CKD
have a higher prevalence of structural and functional LV
and RV abnormalities, which are already apparent in
early CKD (eGFR 60–89 ml/min/1.73m2). We also iden-
tified that RV systolic function or dilation and pulmon-
ary artery pressure are independently associated with a
composite renal outcome of serum creatinine doubling,
dialysis, or transplantation. Both RV and LV echocardio-
graphic features were associated with mortality.
Park et al. analyzed the CRIC population and found
that decreasing renal function was associated with LV
hypertrophy, abnormal LV geometry, diastolic dysfunc-
tion, but not with systolic dysfunction [5]. Gori et al. de-
scribed cardiac structure and function in 217 individuals
with heart failure with preserved ejection fraction from
the PARAMOUNT trial [3]. They found that renal im-
pairment was associated with abnormal LV geometry,
higher LV mass or LV mass index, and lower mid-wall
fractional shortening [3]. Creatinine clearance was also
identified as an independent predictor of heart failure
with preserved ejection fraction in a retrospective study
of patients with hypertension and preserved ejection
fraction [6]. In a cohort of post-myocardial infarction




(95% CI) - Renal
outcomes




LVEF Group 1 vs. 4 67 vs. 649 1.18 (0.88–1.59) 0.26 423 vs. 5602 1.46 (1.31–1.63) < 0.001
Group 2 vs. 4 91 vs. 649 1.06 (0.82–1.36) 0.66 803 vs. 5602 1.27 (1.17–1.38) < 0.001
Group 3 vs. 4 160 vs. 649 1.05 (0.87–1.26) 0.64 1403 vs. 5602 1.09 (1.02–1.16) 0.007
LVd Quartile 2 vs. 1 178 vs. 208 0.77 (0.63–0.95) 0.02 1805 vs. 2211 0.83 (0.78–0.89) < 0.001
Quartile 3 vs. 1 211 vs. 208 0.97 (0.79–1.19) 0.78 1553 vs. 2211 0.80 (0.75–0.86) < 0.001
Quartile 4 vs. 1 292 vs. 208 1.02 (0.83–1.26) 0.83 1872 vs. 2211 0.84 (0.78–0.90) < 0.001
LVMi Quartile 2 vs. 1 42 vs. 56 0.72 (0.47–1.08) 0.11 450 vs. 458 0.93 (0.81–1.06) 0.29
Quartile 3 vs. 1 84 vs. 56 1.29 (0.90–1.84) 0.17 551 vs. 458 0.97 (0.85–1.11) 0.65
Quartile 4 vs. 1 63 vs. 56 0.81 (0.54–1.22) 0.31 626 vs. 458 0.95 (0.83–1.08) 0.41
PAP Quartile 2 vs. 1 167 vs. 115 1.31 (1.02–1.67) 0.03 1452 vs. 1090 1.11 (1.02–1.20) 0.02
Quartile 3 vs. 1 157 vs. 115 1.67 (1.30–2.15) < 0.001 1374 vs. 1090 1.26 (1.16–1.37) < 0.001
Quartile 4 vs. 1 223 vs. 115 2.26 (1.77–2.88) < 0.001 2062 vs. 1090 1.73 (1.60–1.88) < 0.001
RV systolic function Reduced vs. preserved 106 vs. 743 1.51 (1.21–1.88) < 0.001 881 vs. 6494 1.61 (1.49–1.73) < 0.001
RV hypertrophy Present vs. absent 26 vs. 417 1.33 (0.88–2.02) 0.18 204 vs. 3971 1.17 (1.01–1.35) 0.04
RV dilation Present vs. absent 149 vs. 740 1.59 (1.32–1.92) < 0.001 1189 vs. 6414 1.45 (1.36–1.55) < 0.001
Adjusted Cox models. Hazard ratios are adjusted for age, sex, race, baseline eGFR, history of hypertension, diabetes, CAD, or CHF, and use of ACEI and/or ARB.
Composite renal outcome includes doubling of serum creatinine or initiation of maintenance dialysis or kidney transplantation. For LVEF, the following cutoffs
were used: < 25%, 25–39%, 40–54%, ≥55%. HR, hazards ratio; CI, confidence interval; AA, African American race; eGFR, estimated glomerular filtration rate; HTN,
hypertension; CAD, coronary artery disease; CHF, congestive heart failure; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVEF,
left ventricular ejection fraction; LVd, left ventricular diastolic diameter; LVMi, left ventricular mass index (corrected for body surface area); PAP, pulmonary
artery pressure; RV, right ventricle
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patients from the VALIANT trial, worse renal function
was associated with smaller LV, larger left atrial volume,
and higher LV mass index [7]. In contrast, in hyperten-
sive patients with asymptomatic diastolic dysfunction
from the VALIDD and EXCEED trials, eGFR group was
not associated with echocardiographic measures of LV
structure and function [8].
Our findings confirm most of these observations in a
much larger population including patients with and
without CHF. We also report a significant association of
worse renal function with LV systolic impairment, and
we expand the previous findings by looking at RV
parameters and their association with CKD.
We found that only pulmonary artery pressure and
parameters related to the RV are associated with CKD
progression. The AASK study addressed this issue in
African-American patients with pre-existing non-diabetic
hypertensive CKD and showed that LV mass index was
not associated with a combined outcome of doubling of
creatinine or end-stage renal disease [9]. On the contrary,
a retrospective analysis of the Jackson Heart Study, also in
an African-American population, showed a significant
association of LV mass, but not LV ejection fraction or
pulmonary artery pressure, with a composite outcome of
eGFR decline > 30% or progression to end-stage renal dis-
ease [10]. A small cohort study in stage 3–5 CKD patients
demonstrated that concentric LV hypertrophy was associ-
ated with progression to dialysis, whereas LV ejection frac-
tion and increased left atrium diameter were associated
with CKD progression, defined as eGFR decline > 3 ml/
min/1.73m2 annually [11, 12]. In addition, a study in 300
elderly patients showed that LV hypertrophy was inde-
pendently associated with eGFR decline > 5 ml/min/
1.73m2 per year [13]. In the ESCAPE trial, a significant
correlation was identified between baseline creatinine
levels and right atrial pressure levels in patients admitted
with heart failure [14]. Park et al., using magnetic reson-
ance imaging, demonstrated that LV mass and concentri-
city, a measurement of abnormal cardiac size, were
associated with eGFR decline and incident CKD [15].
Discrepancies with our findings may reflect differences in
baseline renal and heart function, demographic characteris-
tics and the use of a clinical cohort in our study compared to
highly selected prospective research or trial cohorts in the
prior studies. Furthermore, renal outcomes were not defined
in the same way. Lack of association between LV mass index
and renal outcomes or mortality in our study may be due to
values below hypertrophic levels for the majority of individ-
uals. LV mass could be more reliably assessed with more ad-
vanced techniques, such as magnetic resonance imaging.
Similarly, lack of association between pulmonary artery pres-
sure and renal outcomes in the Jackson Heart Study may be
due to relatively normal pulmonary artery pressure values
among study participants.
Our findings extend these findings by demonstrating a
significant, independent association between RV diameter
or function and CKD progression in a population that
primarily did not have CHF. Worsening RV function and
elevated pulmonary artery pressures may be associated with
higher renal vein pressures, a purported mechanism under-
lying the cardiorenal syndrome [16, 17]. Similarly, salt and
water retention in the setting of decreasing eGFR may
contribute to volume overload and increased renal vein
pressures that may impair renal perfusion and cause
ischemia-mediated sclerotic changes. On the contrary, LV
dysfunction may not significantly impact renal function
provided that renal perfusion pressure remains in an ac-
ceptable range. However, these findings are only hypothesis
generating and need to be prospectively confirmed. Finally,
we also report a significant association between mortality
and abnormal RV structure or function. No prior data exist
on the association between right heart parameters and
mortality in patients with CKD, to our knowledge.
Our study has several limitations. It is a retrospective
study of patients referred for echocardiography and may not
reflect the complete spectrum of patients with preserved
renal function or mild eGFR impairment since sicker pa-
tients are more likely to be referred for echocardiography
and those with more advanced cardiopulmonary disease are
more likely to have RV dysfunction. Furthermore, no infor-
mation was available on the indication for the echocardio-
gram. Echocardiograms were ordered to answer specific
clinical questions rather than to provide systemic assessment
of cardiac structure and they were interpreted by multiple
clinicians rather than by a core lab, raising the possibility of
confounding introduced by wide inter-reader variability be-
tween sonographers. In particular, RV assessment is fraught
with potential errors of judgment and high degree of
inter-observer variability. Additionally, tissue Doppler im-
aging results, diastolic function, and valve structure and
function were not extractable for most patients.
Index echocardiograms might have been conducted in
the setting of decompensated CHF and may not reflect
baseline cardiac status or could have been followed by
acute changes in kidney function. However, our findings
were qualitatively similar in a subgroup analysis including
only outpatient echocardiograms in which these issues
would be less likely. We similarly cannot rule out the pos-
sibility that addition of renin-angiotensin-system agents in
individuals with more severe echocardiographic changes
partly accounted for associations with CKD progression,
although our results were adjusted for use of these agents
at baseline. Furthermore, the clinical indication of the
echocardiogram may have already caused changes in
eGFR. Capture of medication changes during follow-up is
not readily available to us at this time. Finally, there were
no BP or proteinuria values available for most patients in
this dataset, and no information was available on the cause
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of death. Nevertheless, a sample size several times larger
than all prior cohorts, assessment of multiple echocardio-
graphic parameters, and most importantly a sufficient
number of outcomes to be powered to examine associa-
tions with CKD progression and mortality represent
unique strengths of our analysis.
More studies are needed to prospectively confirm the
identified associations and carefully evaluate the right
heart with comprehensive assessment of the RV includ-
ing lateral tricuspid annular systolic velocity and acceler-
ation, fractional area and long-axis change, tricuspid
annular systolic excursion, myocardial performance
index, and lateral free wall peak systolic strain, as well as
inferior vena cava diameter and distensibility [18, 19].
These results also merit analysis in the setting of ad-
vanced CKD (eGFR < 30 ml/min/1.73m2).
Conclusions
In conclusion, structural and functional abnormalities of
the right and left ventricle are more common in individ-
uals with mild or moderate renal impairment and associ-
ated with mortality while RV function and structure are
independently associated with CKD progression even in
early stage CKD. Prospective studies with quantitative
assessment of the RV are needed to validate our observa-
tions and better understand the underlying mechanisms.
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